ALMR

Alamar Biosciences, Inc. is a biotech company specializing in ultra-sensitive, high-plex protein biomarker detection technologies aimed at advancing precision proteomics for early disease detection and translational research. The company is based in Fremont, CA. The company's proprietary NULISA platform enables multiplexed, high-sensitivity protein assays from small fluid samples, supporting applications in immunology, neurology, oncology, and autoimmune disorders. Key products include the NULISA assay panels, the NULISASeq inflammation panel AQ for quantitative immune biomarker profiling, and the ARGO HT system for automated, high-throughput proteomics analysis with integrated sample processing and cloud-based data analytics. Alamar also offers the Attobody platform and custom assay development services, collaborates with academic, biopharmaceutical, and biotech researchers worldwide, supports large cohort studies, and partners with distributors to ensure access. Yuling Luo has been the CEOs since incorporation. The company was founded by Yiyuan Yin, Yuling Luo, Steve Chen.